Evidence map›Paper›PMID 35480225›Full record

ReviewBrain communications2022

Tissue donations for multiple sclerosis research: current state and suggestions for improvement.

Patrick Vanderdonckt, Francesca Aloisi, Giancarlo Comi, Alexander de Bruyn, Hans-Peter Hartung, Inge Huitinga, Tanja Kuhlmann, Claudia F Lucchinetti, Imke Metz, Richard Reynolds and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Brain communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Tertiary Lymphoid Structures in Central Nervous System Disorders.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 8 countries.

Patrick VanderdoncktDepartment of Neurology, AZ Groeninge, Kortrijk, Belgium.
Francesca AloisiDepartment of Neuroscience, Istituto Superiore di Sanità, Rome, Italy.
Giancarlo ComiCentro Sclerosi Multipla Ospedale Gallarate and European Charcot Foundation, San Rafaele Scientific Institute, Milano, Italy.
Alexander de BruynDepartment of Neurology, UZ Leuven, Leuven, Belgium.
Hans-Peter HartungDepartment of Neurology UKD, Germany Medical Faculty, Heinrich Heine Universität, Düsseldorf, Germany.
Inge HuitingaDepartment of Neuroimmunology, Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Tanja KuhlmannInstitut für Neuropathologie, Universitätsklinikum Münster/UKM, Münster, Germany.
Claudia F LucchinettiDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Imke MetzInstitute of Neuropathology, University Medical Center, Göttingen, Germany.ORCID https://orcid.org/0000-0002-6571-7630
Richard ReynoldsDepartment of Brain Sciences, Imperial College, London, UK.ORCID https://orcid.org/0000-0003-4622-4694
Hans LassmannCenter for Brain Research, Medical University of Vienna, Wien, Austria.
AZ Groeninge · BEImperial College London · GBIstituto Superiore di Sanità · ITMayo Clinic in Arizona · USMedical University of Vienna · ATNetherlands Institute for Neuroscience · NLThe University of Sydney · AUUniversitair Ziekenhuis Leuven · BEUniversitätsmedizin Göttingen · DEUniversity Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although major progress in multiple sclerosis research has been made during the last decades, key questions related to the cause and the mechanisms of brain and spinal cord pathology remain unresolved. These cover a broad range of topics, including disease aetiology, antigenic triggers of the immune response inside and/or outside the CNS and mechanisms of inflammation, demyelination neurodegeneration and tissue repair. Most of these questions can be addressed with novel molecular technologies in the injured CNS. Access to brain and spinal cord tissue from multiple sclerosis patients is, therefore, of critical importance. High-quality tissue is provided in part by the existing brain banks. However, material from early and highly active disease stages is limited. An initiative, realized under the patronage of the European Charcot Foundation, gathered together experts from different disciplines to analyse the current state of multiple sclerosis tissues collected post-mortem or as biopsies. Here, we present an account of what material is currently available and where it can be accessed. We also provide recommendations on how tissue donation from patients in early disease stages could be potentially increased and for procedures of tissue sampling and preservation. We also suggest to create a registry of the available tissues that, depending on the source (autopsy versus biopsy), could be made accessible to clinicians and researchers.

Indexed as

autopsiesbiopsiesbrain bankingmultiple sclerosistissue donation

Identifiers

PMID35480225
PMCPMC9039502
OpenAlexW4225638043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.